ReviewThe Lancet regional health. Europe2025
Reducing inequalities in cardiovascular disease: focus on marginalized populations considering ethnicity and race.
Review in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Real-World Use of Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction Newly Initiated on Dapagliflozin: An EVOLUTION-HF CEE-BA Study (Results from the Baltic Cohort).Medicina (Kaunas, Lithuania) · 2026Article
- Yorga Moorditj Koort: Aboriginal and Torres Strait Islander women's perspectives about heart health on Noongar Boodjar.Health promotion international · 2026Article
- Multimorbidity among indigenous tribal communities in Kerala, India: a cross-sectional study (2022-2024).The Lancet regional health. Southeast Asia · 2026Article
- Heat stress and cardiovascular hospitalizations in a semi-arid megacity: a multi-method epidemiological and machine-learning analysis in Isfahan, Iran.BMC public health · 2026Article
- Review
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- Ethnic differences in the comparative effectiveness of second-line type 2 diabetes medications in preventing cardiovascular disease.Diabetes, obesity & metabolism · 2026Article
- Addressing cardiovascular health disparities: global perspectives from the patient community.The Lancet regional health. Europe · 2025Article
- Equity and cardiovascular disease: time to take it seriously.The Lancet regional health. Europe · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) and its risk factors are more prevalent among traditionally marginalized racial, ethnic, and Indigenous groups. These populations also often face greater barriers to accessing cardiovascular health care, further contributing to the health equity gap. To address the challenge of inequalities and disparities in cardiovascular health outcomes, the Lancet Regional Health-Europe convened experts to evaluate the current state of knowledge on inequalities and disparities in cardiovascular health among marginalized populations and propose recommendations to address these disparities. This Series paper aims to review disparities in CVD referring to coronary heart disease and stroke, based on race, ethnicity, ancestry, and Indigeneity emphasizing the intersection of these factors with sex, gender, and socioeconomic status (SES) across Europe and North America. These regions were chosen as they have well established health-care systems, with persistent, and in some regions widening, disparities in cardiovascular health and outcomes. Ethnicity and race should be measured in a standardized manner in health-care administrative databases to identify high risk groups who might need focused programmes to improve health-care access and to address bias and inequities in care. Strategies that policymakers, health-care professionals, and advocacy groups can use to advance cardiovascular health equity include improving access to health-care systems and research for high-risk communities, fostering trust between these communities and public health providers, and enhancing the delivery of evidence-based therapies for the prevention and treatment of CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.